Abstract
Overview
Introduction
Increased prevalence of diabetes, obesity, and cardiovascular disease, all
causal factors of renal disease, drives growth of the end-stage renal disease
(ESRD) sector. On average, an ESRD patient uses >$7,000 of drugs/year,
representing a significant opportunity for pharmaceutical companies in
treating the symptoms, comorbid conditions and treatment side effects of ESRD.
Scope
- Analysis of the ESRD sector in the US, and in the 5 major European markets
Germany, France, UK, Italy and Spain
- Analysis of issues facing the ESRD market: rising prevalence, treatment
costs and greater focus on prevention, and differences in treatment patterns
- Insight into drugs in the treatment of comorbidities of ESRD including:
hypertension, dyslipidemia and diabetes
- Review of drugs in the treatment of dialysis side effects including:
erythropoietins, IV iron, vitamin D and phosphate lowering drugs
Report Highlights
The ESRD market is growing at a rate of 6% in the US, 7% in Japan and 4% in
Europe. It is a large cost burden on healthcare payors with treatment costs
increasing by a CAGR of 5% to over $60,000 per patient per year.
Diabetes and hypertension are considered a causal factor in >72% of the cases
of ESRD and cardiovascular disease is the cause of death for over 60% of ESRD
patients. The ESRD market represents around 1% of the cardiovascular market,
but the overall chronic kidney disease (CKD) market is a much larger target
population.
Costs of drugs directly treating symptoms of ESRD represent over 14% of the
treatment costs. Erythropoietin treatment of renal-disease-related anemia
represents over 70% of these costs, followed by vitamin D treatment of
secondary hyperparathyroidism. Costs are expected to reduce with the
introduction of biosimilars or biogenerics in 2007 to 2010.
Reasons to Purchase
- Gain insight into the dynamics and key issues in the ESRD market
- Understand how to position drugs used to treat the comorbidities of ESRD
patients
- Look at the opportunities in treating dialysis patients
| 
View Cart
